Actualités

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J’s MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon […]

Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of litigation over alleged health risks tied to the company’s talc-based products. The settlement follows years of high profile trials and failed bankruptcy attempts related to the talc claims. This resolution removes a long running legal overhang and brings more clarity for Johnson & Johnson investors. Consider broadening your research to other large...

Johnson & Johnson proposed a $5.5b settlement to resolve tens of thousands of ovarian cancer talc lawsuits. The offer aims to address a decade-long legal dispute involving the company’s talcum powder products. The settlement would require approval from a majority of claimants before it can move forward. For investors watching Johnson & Johnson (NYSE:JNJ), this legal development sits alongside a stock that closed at $265.53 and has recently shown strong momentum. The shares are up 3.9% over...

Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.

Johnson & Johnson has set aside $5.5 billion to resolve tens of thousands of US lawsuits alleging that its talcum powder-based products caused ovarian cancer.

The deal covers about 76,000 ovarian cancer claims and requires acceptance by at least 95% of claimants to take effect

Johnson & Johnson has offered $5.5 billion to settle tens of thousands of lawsuits claiming its baby powder and other talcum powder products caused ovarian cancer, the company says.

Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer. The company said the settlement covers around 76,000 claims, having already settled most cases alleging its talc contained asbestos and caused mesothelioma. J&J's vice president of litigation, Erik Haas, said the move was motivated by a desire to get closure – describing the claims themselves as "meritless".

The company said it reached an agreement with firms representing plaintiffs in the outstanding talc cases to pay up to $3 billion in claim payments in 2027, with no further payments due before 2028.

The U.S. Food and Drug Administration on Wednesday granted De Novo authorization for Johnson & Johnson’s OTTAVA Robotic Surgical System, marking the regulatory clearance of the world’s first table-integrated soft tissue robotic platform. The marketing clearance encompasses multiple general surgery...

Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.

Johnson & Johnson (NYSE:JNJ) is one of the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds. On June 6, Reuters reported that a Los Angeles jury found Johnson & Johnson (NYSE:JNJ) was not negligent in a lawsuit alleging its talc products led to ovarian cancer in three women. Reuters said the lawsuit […]